Eli Lilly and Company, incorporated in 1901 in Indiana, discovers, develops, manufactures, and markets human pharmaceutical products worldwide. Operating in a single business segment, Lilly sells products in approximately 90 countries across therapeutic areas including cardiometabolic health (Mounjaro, Zepbound, Jardiance, Humalog), oncology (Verzenio, Cyramza, Retevmo, Jaypirca), immunology (Ebglyss, Olumiant), and neuroscience. The company manufactures and distributes through facilities in the U.S., Puerto Rico, Europe, and Asia.
Q2 FY2026 — expected 2026-08-11
| Type | Subject | Detail | Quarter |
|---|---|---|---|
| topic_mention | LLY | discussed Automotive | |
| topic_mention | LLY | discussed Blockchain & Crypto | |
| topic_mention | LLY | discussed Semiconductor | |
| topic_mention | LLY | discussed Capital Expenditure | |
| topic_mention | LLY | discussed Regulation | |
| topic_mention | LLY | discussed Automotive | |
| topic_mention | LLY | discussed Healthcare & Bio | |
| metric | LLY total revenue | reported $45.0 billion | |
| metric | LLY gross margin | reported $83.2 percent | |
| metric | LLY gross margin | reported $82.2 percent | |
| metric | LLY gross margin | reported $38.0 percent | |
| metric | LLY gross margin | reported $81.3 percent | |
| metric | LLY gross margin | reported $28.6 percent | |
| metric | LLY gross margin | reported $47 percent | |
| metric | LLY gross margin | reported $46 percent | |
| metric | LLY EPS | reported $4.88 | |
| metric | LLY EPS | reported $11.71 | |
| guidance | LLY | guided Guidance REVENUE $45.0 billion | |
| guidance | LLY | guided FY 2024 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO EXCLUDE: • asset impairment, restructuring and other special charges totaling $860.6 million | |
| guidance | LLY | guided FY 2023 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO EXCLUDE: • amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-12 | 2025-12-31 | 0000059478-26-000013 | EDGAR | 58K words |
| 2025-02-19 | 2024-12-31 | 0000059478-25-000067 | EDGAR | — |
| 2024-02-21 | 2023-12-31 | 0000059478-24-000065 | EDGAR | — |
| 2023-02-22 | 2022-12-31 | 0000059478-23-000082 | EDGAR | — |
| 2022-02-23 | 2021-12-31 | 0000059478-22-000068 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-04-30 | 2026-03-31 | 0000059478-26-000045 | EDGAR | — |
| 2025-10-30 | 2025-09-30 | 0000059478-25-000254 | EDGAR | 23K words |
| 2025-08-07 | 2025-06-30 | 0000059478-25-000204 | EDGAR | — |
| 2025-05-01 | 2025-03-31 | 0000059478-25-000132 | EDGAR | — |
| 2024-10-30 | 2024-09-30 | 0000059478-24-000245 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000059478-24-000187 | EDGAR | — |
| 2024-04-30 | 2024-03-31 | 0000059478-24-000118 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0000059478-23-000284 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0000059478-23-000221 | EDGAR | — |
| 2023-04-27 | 2023-03-31 | 0000059478-23-000162 | EDGAR | — |
| 2022-11-01 | 2022-09-30 | 0000059478-22-000250 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0000059478-22-000196 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-05-20 | 0001193125-26-232707 | EDGAR | — |
| 2026-05-07 | 0000059478-26-000048 | EDGAR | — |
| 2026-04-30 | 0000059478-26-000043 | EDGAR | — |
| 2026-02-04 | 0000059478-26-000008 | EDGAR | 6K words |
| 2025-11-21 | 0000059478-25-000271 | EDGAR | — |
| 2025-10-30 | 0000059478-25-000251 | EDGAR | — |
| 2025-08-20 | 0001193125-25-184093 | EDGAR | — |
| 2025-08-07 | 0000059478-25-000202 | EDGAR | — |
| 2025-05-08 | 0000059478-25-000138 | EDGAR | — |
| 2025-05-01 | 0000059478-25-000129 | EDGAR | — |
74 total filings indexed. 47 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| Call Date | Quarter | Title |
|---|---|---|
| — | LLY Earnings Call Transcript | |
| — | LLY Earnings Call Transcript | |
| — | LLY Earnings Call Transcript | |
| — | LLY Earnings Call Transcript | |
| — | LLY Earnings Call Transcript | |
| — | LLY Earnings Call Transcript | |
| — | LLY Earnings Call Transcript | |
| — | LLY Earnings Call Transcript | |
| — | LLY Earnings Call Transcript | |
| — | LLY Earnings Call Transcript | |
| — | LLY Earnings Call Transcript | |
| — | LLY Earnings Call Transcript |
32 more transcripts.
Access full transcripts via API (JSON) — includes speakers, key metrics, competitive mentions, and origin provenance chain.
| CIK | 0000059478 |
| Ticker | LLY |
| Exchange | NYSE |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | IN |
| Headquarters | Indianapolis, Indiana |
| Website | https://www.lilly.com |
| Listed | 1970-07-09 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report